Theralizumab Biosimilar - Research Grade

Specifications

Catalog number

ICH5023-100mg

Size / count

100 mg

Dry ice

No

Hazardous

No

Discontinued

No

Background

Theralizumab GN1412 is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system’s T cells. CD28 is the co-receptor for the T cell receptor; It binds to receptors on the interacting partner in the reaction through one of its ligands (B7 family). It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by PAREXEL in London in March 2006.

Specifications

Detects human CD28. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Theralizumab.

Product Name Alternative

TGN1412, CD28-SuperMAB, TAB08

UniProt

P10747

Species Reactivity

Human

Target

CD28

Isotype

IgG4

Applications

Functional Assays

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Concentration

5mg/mL

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE

Buffer

ICH3002

Shipping Conditions

Blue ice

Storage Conditions

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Applications Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Isotype Control

https://ichor.bio/product/bulk-human-igg4-isotype-control-ib4-ich2257/